Literature DB >> 10651024

Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans.

H Tomimoto1, I Akiguchi, H Wakita, J X Lin, H Budka.   

Abstract

Cyclooxygenase-2 (COX-2) is known to be up-regulated in ischemic rodent brains, but only little information is available for the human brain. Using immunohistochemistry for COX-2, we investigated brains from control subjects and from patients with cerebrovascular diseases. COX-2 was markedly up-regulated in the neurons and endothelial cells in acute cerebral infarction, but was detected sparsely at chronic stages in these cellular compartments. In contrast, COX-2 immunoreactivity in glial cells was localized to the perinuclear region even in control brains. This immunolabeling was more intense and occurred also in the glial cytoplasm in the brains with chronic cerebral ischemia such as Binswanger's disease. Double-labeling immunohistochemistry confirmed that COX-2-immunoreactive glia were mostly microglia. These results indicate that prostanoid synthesis is up-regulated in microglia during chronic cerebral ischemia, and that these cells may be involved in tissue repair or inflammation-mediated cell responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651024     DOI: 10.1007/pl00007402

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  14 in total

1.  Animal Models of Posttraumatic Seizures and Epilepsy.

Authors:  Alexander V Glushakov; Olena Y Glushakova; Sylvain Doré; Paul R Carney; Ronald L Hayes
Journal:  Methods Mol Biol       Date:  2016

2.  Serum deprivation and re-addition: effects on cyclooxygenase inhibitor sensitivity in cultured glia.

Authors:  James Phillips; Brian Pearce
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

3.  Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury.

Authors:  Yuri Ikeda-Matsuo; Azusa Ota; Tetsuya Fukada; Satoshi Uematsu; Shizuo Akira; Yasuharu Sasaki
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

4.  The COX-2 inhibitors, meloxicam and nimesulide, suppress neurogenesis in the adult mouse brain.

Authors:  Maria Beatriz Goncalves; Emma-Jane Williams; Ping Yip; Rafael J Yáñez-Muñoz; Gareth Williams; Patrick Doherty
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

5.  Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases.

Authors:  Won-Kyo Jung; Da-Young Lee; Cheol Park; Yung Hyun Choi; Inhak Choi; Sae-Gwang Park; Su-Kil Seo; Soo-Woong Lee; Sung Su Yea; Soon-Cheol Ahn; Chang-Min Lee; Won Sun Park; Jae-Hong Ko; Il-Whan Choi
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

6.  Microsomal prostaglandin E synthase-1 and cyclooxygenase-2 are both required for ischaemic excitotoxicity.

Authors:  Y Ikeda-Matsuo; Y Hirayama; A Ota; S Uematsu; S Akira; Y Sasaki
Journal:  Br J Pharmacol       Date:  2010-01-29       Impact factor: 8.739

7.  Neuronal cyclooxygenase-2 activity and prostaglandins PGE2, PGD2, and PGF2 alpha exacerbate hypoxic neuronal injury in neuron-enriched primary culture.

Authors:  Wenjin Li; Shasha Wu; Robert W Hickey; Marie E Rose; Jun Chen; Steven H Graham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

8.  Cyclooxygenase-1-dependent prostaglandins mediate susceptibility to systemic inflammation-induced acute cognitive dysfunction.

Authors:  Éadaoin W Griffin; Donal T Skelly; Carol L Murray; Colm Cunningham
Journal:  J Neurosci       Date:  2013-09-18       Impact factor: 6.167

9.  Inflammation and white matter damage in vascular cognitive impairment.

Authors:  Gary A Rosenberg
Journal:  Stroke       Date:  2008-12-08       Impact factor: 7.914

10.  Prostaglandin F2α FP receptor antagonist improves outcomes after experimental traumatic brain injury.

Authors:  Alexander V Glushakov; Sean W Robbins; Connor L Bracy; Shuh Narumiya; Sylvain Doré
Journal:  J Neuroinflammation       Date:  2013-10-30       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.